文献速递肝病

肝细胞CMPK2促进代谢功能障碍相关脂肪性肝炎的发展

Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis.
PubMed 文献 · J Hepatol · 2025-01-22

研究利用GEO数据库和MASH患者肝组织筛选差异基因,在多种小鼠MASH模型中验证CMPK2的功能,并通过表面等离子共振成像联合间接酶活性检测发现CMPK2抑制剂。CMPK2在肥胖MASH患者和小鼠肝脏中显著上调,肝细胞特异性敲除Cmpk2可减轻肝损伤、炎症和纤维化,去甲二氢愈创木酸抑制CMPK2可抑制NLRP3炎症小体激活和肝细胞焦亡。

要点

  • CMPK2在MASH阶段上调,而在MASLD早期阶段不上调。
  • 肝细胞特异性Cmpk2敲除减轻饮食诱导小鼠的肝损伤、炎症和纤维化。
  • 去甲二氢愈创木酸抑制CMPK2,抑制NLRP3炎症小体激活和肝细胞焦亡。

核心结论

  • CMPK2是MASLD向MASH进展的关键介质,并可能是代谢疾病治疗的潜在靶点。

研究设计与样本

  • 利用Gene Expression Omnibus数据库和MASH患者肝组织鉴定MASH差异表达基因。
  • 在肝细胞特异性过表达小鼠、条件性敲除小鼠和多种小鼠MASH模型中评估CMPK2的功能作用。
  • 通过表面等离子共振成像联合间接酶活性检测发现CMPK2抑制剂。

主要发现

  • CMPK2在肥胖MASH个体和小鼠饮食诱导MASH的肝脏中显著上调。
  • 肝细胞特异性Cmpk2缺失显著减轻小鼠肝损伤、炎症和纤维化。
  • 通过基因操作或去甲二氢愈创木酸药物干预抑制CMPK2,抑制NLRP3炎症小体激活及随后的肝细胞焦亡。
  • 去甲二氢愈创木酸在体内减轻饮食诱导的代谢紊乱、炎症和纤维化。

局限性

  • 原文未报告局限性。

以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。

原文

BACKGROUND & AIMS: There are limited pharmacological treatment options for metabolic dysfunction-associated steatohepatitis (MASH), the progressive form of metabolic dysfunction-associated steatotic liver disease (MASLD). Therefore, we aimed to identify novel therapeutic targets. METHODS: The Gene Expression Omnibus database and human liver tissues obtained from patients with MASH were used to identify differentially expressed genes in MASH. The functional role of cytidine/uridine monophosphate kinase 2 (CMPK2) was assessed in mice with hepatocyte-specific overexpression, conditional knockout mice, and several murine MASH models. CMPK2 inhibitors were discovered through surface plasmon resonance imaging coupled with indirect enzyme activity detection. RESULTS: CMPK2, a critical enzyme involved in mitochondrial DNA synthesis, exhibited significant upregulation in the livers of obese individuals with MASH and mice with diet-induced MASH. Hepatocyte-specific Cmpk2 deletion substantially mitigated liver injury, inflammation, and fibrosis in mice. Inhibition of CMPK2, either through genetic manipulation or pharmacological intervention with nordihydroguaiaretic acid, suppressed Nlrp3 (NOD-like receptor family pyrin domain containing 3) inflammasome activation and subsequent hepatic pyroptosis. Furthermore, nordihydroguaiaretic acid alleviated diet-induced metabolic disorders, inflammation, and fibrosis in vivo. CONCLUSIONS: These findings establish CMPK2 as a critical mediator in the progression from metabolic dysfunction-associated steatotic liver to MASH and highlight its potential as a therapeutic target for metabolic diseases. IMPACT AND IMPLICATIONS: Cytidine/uridine monophosphate kinase 2 (CMPK2) is upregulated in the metabolic dysfunction-associated steatohepatitis (MASH) stage but not in the early stages of metabolic dysfunction-associated steatotic liver disease. Our study demonstrated that diet-induced MASH phenotypes, including liver injury, inflammation, and fibrosis were alleviated in hepatocyte-specific Cmpk2-knockout mice. These findings suggest that CMPK2 serves as a critical link in the progression of steatotic liver to steatohepatitis, offering novel mechanistic insights into MASH development. Furthermore, this discovery identified CMPK2 as a promising target for the development of therapeutic drugs for MASH.

来源:J Hepatol,查看原文。版权归原作者所有。

引用

  1. Zhu S, Liao L, Zhong Y, et al. Hepatocellular CMPK2 promotes the development of metabolic dysfunction-associated steatohepatitis. J Hepatol. 2025. PMID: 39855350. doi:10.1016/j.jhep.2025.01.008

供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。